BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer [Yahoo! Finance]
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Yahoo! Finance
The EC has approved Opdivo plus Yervoy for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC). Following the latest nod, Opdivo plus Yervoy became the first dual checkpoint inhibitor therapy to be approved for the first-line treatment of MSI-H/dMMR mCRC in the European Union. The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Opdivo plus Yervoy for the given indication in November. Year to date, shares of Bristol Myers have rallied 12.2% against the industry's decline of 13.7%. Zacks Investment Research Image Source: Zacks Investment Research Approval Based on BMY's CheckMate -8HW Study The latest approval for Opdivo plus Yervoy in first-line MSI-H/dMMR mCRC was based on data from the phase III CheckMate -8HW study. Data from the same showed that treatment with the combo of Opdivo plus Yer
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development [Yahoo! Finance]Yahoo! Finance
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate DevelopmentGlobeNewswire
- 3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 [Yahoo! Finance]Yahoo! Finance
- Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term [Yahoo! Finance]Yahoo! Finance
- Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 11/6/24 - Beat
IMCR
Sec Filings
- 1/3/25 - Form 4
- 1/2/25 - Form 8-K
- 11/14/24 - Form SC
- IMCR's page on the SEC website